BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
January 21, 2020 07:00 ET
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China
January 13, 2020 07:00 ET
|
BeiGene, LTD.
- SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China – - Expands EUSA’s global product offering; broadens BeiGene’s portfolio – HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and...
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 07:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
January 02, 2020 08:15 ET
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies
December 27, 2019 22:30 ET
|
BeiGene, LTD.
Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and...
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma
December 22, 2019 18:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Dec. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
December 16, 2019 07:00 ET
|
BeiGene, LTD.
- Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)-...
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
December 13, 2019 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting
December 08, 2019 16:45 ET
|
BeiGene, LTD.
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 26, 2019 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...